Two pumps, one algorithm. The t:slim X2 is the established touchscreen pump; Mobi is the smallest durable AID pump in the world, controlled entirely from your phone. Both run Control-IQ — and the newer Control-IQ+ technology now cleared for type 2 diabetes.
Device specifications change frequently — always verify current information directly with the manufacturer before making any decisions. Full disclaimer.
New to Tandem? Start here.
Tandem Diabetes Care makes two automated insulin delivery pumps that share the same underlying algorithm. The t:slim X2 is the established touchscreen pump — a rechargeable, slim device with an on-pump color touchscreen. Mobi is the newer pump: the smallest durable automated insulin delivery pump in the world, with no screen, controlled entirely from a smartphone app. Both run Tandem's Control-IQ technology, and the newer Control-IQ+ is now FDA-cleared for type 2 diabetes as well as type 1.
Which Pump?The t:slim X2 has an on-pump color touchscreen for bolusing and settings — the established Tandem experience. Slim, rechargeable, and updatable via software (Tandem pioneered remote software updates for pumps).
No disposable batteries — the t:slim X2 charges via USB, typically topping up during daily routines. A few minutes of charging adds meaningful runtime.
Runs Control-IQ+ technology — predictive automation adjusting basal and delivering automatic correction boluses. Now cleared for both type 1 and type 2 diabetes.
Works with Dexcom G6, Dexcom G7, and FreeStyle Libre 2 Plus / Libre 3 Plus — giving patients meaningful CGM flexibility within an established AID system.
Mobi is the smallest durable AID pump in the world — small enough to tuck into a pocket, clip discreetly, or wear in a variety of ways. Durable (not disposable) with replaceable cartridges.
Mobi has no screen — it's controlled entirely from the Tandem Mobi app on your phone. Full bolusing, settings, and automation management happen from the app.
Despite having no screen, Mobi includes an on-pump button for delivering a quick bolus without the phone — useful when the phone isn't handy.
Mobi runs the same Control-IQ+ automation as the t:slim X2 — so the therapy behavior is consistent across both Tandem pumps. The difference is form factor and control, not the algorithm.
Tandem's bet is that different people want different hardware for the same therapy. t:slim X2 for those who want an on-pump touchscreen; Mobi for those who want the smallest possible pump run from their phone — both driven by the same Control-IQ+ algorithm.
— Juicebox Podcast Tandem Guidet:slim X2: touchscreen, rechargeable, 300-unit cartridge. Mobi: smallest durable AID pump, phone-controlled, 200-unit cartridge, on-pump quick-bolus button. Both run Control-IQ+.
Predictive basal adjustment plus automatic correction boluses. Control-IQ+ is now FDA-cleared for type 2 diabetes in addition to type 1 — a meaningful expansion of the eligible population.
Dexcom G6/G7 and FreeStyle Libre 2 Plus / Libre 3 Plus. Confirm current cleared pairings and age indications for the specific pump and region before prescribing.
Standard programmable settings (basal, ICR, ISF/correction factor, DIA, targets) drive Control-IQ+. Your tuning matters as with any programmable AID pump. Software updates delivered remotely via t:connect.
Because both Tandem pumps share Control-IQ+, the therapy behavior is consistent — the practical decision is about hardware and control style. Here's how the algorithm works and how to think about which pump fits.
t:slim X2 vs Mobi| Feature | t:slim X2 | Mobi |
|---|---|---|
| Control | On-pump touchscreen + phone | Phone app (no screen) + quick-bolus button |
| Size | Slim touchscreen pump | World's smallest durable AID pump |
| Cartridge | 300 units | 200 units |
| Algorithm | Control-IQ+ | Control-IQ+ |
| CGM | Dexcom G6/G7, Libre 2 Plus/3 Plus | Dexcom G6/G7, Libre 2 Plus/3 Plus |
| Power | Rechargeable (USB) | Rechargeable (charging tray) |
Patients who want an on-pump touchscreen and the ability to operate the pump fully without a phone. Larger 300-unit cartridge suits higher-TDD patients. Established, familiar Tandem experience.
Patients who prioritize discretion and the smallest possible pump, and are comfortable managing therapy from a phone. On-pump quick-bolus button covers phone-free moments. Smaller 200-unit cartridge.
Control-IQ+ leans on good foundational settings. Review basal, ICR, correction factor, and DIA. Reinforce correct use of Sleep and Exercise modes — misuse or non-use is a common reason results underperform expectations.
Confirm CGM pairing (Dexcom or Libre) and data-sharing setup (t:connect). Consistent CGM data quality directly affects algorithm performance. Verify current age indications and cleared pairings before prescribing.
Tandem's Control-IQ has one of the deeper clinical evidence bases among commercial AID systems, and the platform's remote-update model and dual-pump strategy make it distinctive. Here's the fuller picture for clinicians and power users.
Touchscreen, rechargeable, 300-unit cartridge. Full on-pump operation plus phone bolus via t:connect. Remotely updatable software. Runs Control-IQ+.
World's smallest durable AID pump. Phone-controlled (no screen), on-pump quick-bolus button, 200-unit cartridge, charging tray. Runs Control-IQ+.
Predictive basal adjustment (~30-min horizon) plus automatic correction boluses. Sleep and Exercise activity modes. Cleared for T1D and T2D. Uses standard programmable settings.
Dexcom G6/G7 and FreeStyle Libre 2 Plus / Libre 3 Plus. Confirm current cleared pairings and age indications per pump and region.
Control-IQ pivotal RCTs (DCLP3, Brown et al. NEJM 2019; pediatric Breton et al. NEJM 2020) showed TIR gains vs SAP without increased hypoglycemia. Control-IQ+ builds on this lineage.
t:connect app and web for data review. Tandem pioneered remote pump software updates — pumps can gain features over their lifespan. Availability varies by model/region.